WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H414787
CAS#: 155-09-9 (free base)
Description: Tranylcypromine Free Base is a propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders.
Hodoodo Cat#: H414787
Name: Tranylcypromine Free Base
CAS#: 155-09-9 (free base)
Chemical Formula: C9H11N
Exact Mass: 133.09
Molecular Weight: 133.190
Elemental Analysis: C, 81.16; H, 8.32; N, 10.52
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Related CAS #: 13492-01-8 (sulfate) 155-09-9 (free base) 54779-58-7 (Cis_HCl) 4548-34-9 (HCl)
Synonym: Tranylcypromine Free Base; CCRIS3344; CCRIS-3344; CCRIS 3344; HSDB3404; HSDB-3404; HSDB 3404
IUPAC/Chemical Name: Cyclopropanamine, 2-phenyl-, (1R,2S)-rel-
InChi Key: AELCINSCMGFISI-DTWKUNHWSA-N
InChi Code: InChI=1S/C9H11N/c10-9-6-8(9)7-4-2-1-3-5-7/h1-5,8-9H,6,10H2/t8-,9+/m0/s1
SMILES Code: N[C@H]1[C@H](C2=CC=CC=C2)C1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 133.19 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Dai XJ, Liu Y, Xiong XP, Xue LP, Zheng YC, Liu HM. Tranylcypromine Based Lysine-Specific Demethylase 1 Inhibitor: Summary and Perspective. J Med Chem. 2020 Dec 10;63(23):14197-14215. doi: 10.1021/acs.jmedchem.0c00919. Epub 2020 Sep 30. Erratum in: J Med Chem. 2021 May 13;64(9):6412. PMID: 32931269.
2: LEES F, BURKE CW. Tranylcypromine. Lancet. 1963 Jan 5;1(7271):13-6. doi: 10.1016/s0140-6736(63)91144-9. PMID: 13929197.
3: Atkinson RM, Ditman KS. Tranylcypromine: a review. Clin Pharmacol Ther. 1965 Sep-Oct;6(5):631-55. doi: 10.1002/cpt196565631. PMID: 5320592.
4: Heijnen WT, De Fruyt J, Wierdsma AI, Sienaert P, Birkenhäger TK. Efficacy of Tranylcypromine in Bipolar Depression: A Systematic Review. J Clin Psychopharmacol. 2015 Dec;35(6):700-5. doi: 10.1097/JCP.0000000000000409. PMID: 26479223.
5: Ulrich S, Ricken R, Adli M. Tranylcypromine in mind (Part I): Review of pharmacology. Eur Neuropsychopharmacol. 2017 Aug;27(8):697-713. doi: 10.1016/j.euroneuro.2017.05.007. Epub 2017 Jun 24. PMID: 28655495.
6: Wang X, Su M, Li Y, Liu T, Wang Y, Chen Y, Tang L, He YP, Ding X, Yu F, Shen J, Li J, Zhou Y, Chen YL, Xiong B. Tranylcypromine and 6-trifluoroethyl thienopyrimidine hybrid as LSD1 inhibitor. Bioorg Med Chem Lett. 2019 Mar 15;29(6):844-847. doi: 10.1016/j.bmcl.2019.01.017. Epub 2019 Jan 18. PMID: 30713023.
7: Frieling H, Bleich S. Tranylcypromine: new perspectives on an "old" drug. Eur Arch Psychiatry Clin Neurosci. 2006 Aug;256(5):268-73. doi: 10.1007/s00406-006-0660-8. PMID: 16927039.
8: Park H, Han KM, Jeon H, Lee JS, Lee H, Jeon SG, Park JH, Kim YG, Lin Y, Lee YH, Jeong YH, Hoe HS. The MAO Inhibitor Tranylcypromine Alters LPS- and Aβ- Mediated Neuroinflammatory Responses in Wild-type Mice and a Mouse Model of AD. Cells. 2020 Aug 28;9(9):1982. doi: 10.3390/cells9091982. PMID: 32872335; PMCID: PMC7563969.
9: Fioravanti R, Romanelli A, Mautone N, Di Bello E, Rovere A, Corinti D, Zwergel C, Valente S, Rotili D, Botrugno OA, Dessanti P, Vultaggio S, Vianello P, Cappa A, Binda C, Mattevi A, Minucci S, Mercurio C, Varasi M, Mai A. Tranylcypromine-Based LSD1 Inhibitors: Structure-Activity Relationships, Antiproliferative Effects in Leukemia, and Gene Target Modulation. ChemMedChem. 2020 Apr 3;15(7):643-658. doi: 10.1002/cmdc.201900730. Epub 2020 Feb 14. PMID: 32003940; PMCID: PMC7125024.
10: van der Heide D, Merckelbach H, van Harten P. Tranylcypromine en khat: een potentieel fatale combinatie [Tranylcypromine and khat: a potentially fatal combination]. Tijdschr Psychiatr. 2018;60(8):544-547. Dutch. PMID: 30132583.
